Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Drug Dosing: Geriatric Patients01:15

Drug Dosing: Geriatric Patients

229
Elderly individuals encompass a diverse population with varying degrees of age-related physiological changes. Defining the elderly presents challenges, as the geriatric population is often arbitrarily categorized as individuals older than 65. However, many individuals in this group lead active and healthy lives, with an increasing number surpassing 85 years and falling into the older elderly category. Physiological changes associated with aging impact performance capacity and homeostatic...
229
Pharmacodynamics in Geriatric Patients: Effects of Age01:27

Pharmacodynamics in Geriatric Patients: Effects of Age

193
Age-related pharmacokinetic changes are extensively documented, but understanding age-related pharmacodynamic alterations is relatively limited. This knowledge gap can be partly attributed to the complexity of developing appropriate measures of drug responses compared to bioanalytical methods for determining drug concentrations.Most information regarding age-related differences in human pharmacodynamics originates from cross-sectional studies. However, these studies assume that observed mean...
193
Pharmacokinetics in Geriatric Patients: Effect of Age on Drug Distribution01:00

Pharmacokinetics in Geriatric Patients: Effect of Age on Drug Distribution

237
Drug distribution in the human body is influenced by several factors, including plasma protein concentration, body composition, blood flow, tissue-protein concentration, and tissue fluid pH. Among these, changes in plasma protein concentration and body composition due to aging significantly affect how drugs are distributed within the body. Specifically, aging is associated with a decrease in albumin levels by about 10% and an increase in α1-acid glycoprotein levels. These alterations are...
237
Pharmacokinetics in Geriatric Patients: Effect of Age on Drug Metabolism01:18

Pharmacokinetics in Geriatric Patients: Effect of Age on Drug Metabolism

203
Geriatric patients show significant variation in how their bodies process medications, which can change how effective and safe treatments are. The liver is the primary organ where drug metabolism occurs, involving two main types of chemical reactions: phase I and II. Phase I metabolism is driven by the cytochrome P450 enzyme system, which includes key types such as CYP3A, CYP2D6, and CYP2C9. Research indicates that while aging doesn't notably alter the levels or activity of these enzymes, it...
203
Pharmacokinetics in Geriatric Patients: Effect of Age on Drug Excretion01:18

Pharmacokinetics in Geriatric Patients: Effect of Age on Drug Excretion

245
In geriatric patients, renal physiology undergoes significant changes, including diminished renal blood flow and a lower glomerular filtration rate (GFR), leading to alterations in medication clearance. Drugs such as aminoglycoside antibiotics, lithium, and digoxin, which rely on glomerular filtration for removal from the body, particularly impact pharmacokinetics. These drugs tend to have slower clearance rates in older adults, necessitating careful dosage considerations.Evaluation of renal...
245
Pharmacokinetics in Geriatric Patients: Effect of Age on Drug Absorption01:22

Pharmacokinetics in Geriatric Patients: Effect of Age on Drug Absorption

259
As individuals age, their body's physiology evolves, affecting drug pharmacokinetics. The most apparent changes occur in the gastrointestinal tract, where an increase in gastric pH, a delay in gastric emptying, and a reduction in gastrointestinal motility are observed. Remarkably, these changes do not substantially modify the absorption of orally administered drugs, particularly those absorbed via passive diffusion.Transdermal drug delivery emerges as a highly viable method for older adults due...
259

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Democratising health and social care research through long-term public involvement and engagement: a qualitative process evaluation of the Community Research and Engagement Network (CoREN).

Research involvement and engagement·2026
Same author

Quantitative systems toxicology: modelling to mechanistically understand and predict drug safety.

Nature reviews. Drug discovery·2025
Same author

Neuroendocrine Tumours in the Gastrointestinal Tract: What You Need to Know.

British journal of hospital medicine (London, England : 2005)·2025
Same author

Long-term outcomes of patients treated with contact X-ray brachytherapy and external beam (chemo)radiotherapy following local excision of rectal adenocarcinoma.

European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology·2025
Same author

Patient-Reported Functional Outcomes and Quality of Life After Contact X-Ray Brachytherapy (CXB) in Organ-Preserving Management of Rectal Cancer.

Cancers·2025
Same author

Clinical Prediction Models for Contact X-Ray Brachytherapy in Managing Rectal Cancers: A Scoping Review.

Cancer medicine·2025

Related Experiment Video

Updated: Jan 26, 2026

Production of Nurr-1 Specific Polyclonal Antibodies Free of Cross-reactivity Against Its Close Homologs, Nor1 and Nur77
12:30

Production of Nurr-1 Specific Polyclonal Antibodies Free of Cross-reactivity Against Its Close Homologs, Nor1 and Nur77

Published on: August 17, 2015

7.9K

Recharacterization data for a geriatric gastrin polycolonal antibody.

Steven Dodd1, Andrea Varro1, D Mark Pritchard1

  • 1Department of Cellular and Molecular Physiology, Institute of Translational Medicine, University of Liverpool, Crown St, Liverpool, L69 3BX, UK.

Data in Brief
|April 24, 2019
PubMed
Summary
This summary is machine-generated.

This study recharacterizes a gastrin polyclonal antibody using radioimmunoassay. It details antibody specificity, matrix effects, and establishes reference ranges for fasting gastrin levels in healthy individuals.

Keywords:
AntibodyGastrinRadioimmunoassay validation

More Related Videos

Kinematics and Ground Reaction Force Determination: A Demonstration Quantifying Locomotor Abilities of Young Adult, Middle-aged, and Geriatric Rats
10:28

Kinematics and Ground Reaction Force Determination: A Demonstration Quantifying Locomotor Abilities of Young Adult, Middle-aged, and Geriatric Rats

Published on: February 22, 2011

20.1K
Generation of Murine Monoclonal Antibodies by Hybridoma Technology
09:42

Generation of Murine Monoclonal Antibodies by Hybridoma Technology

Published on: January 2, 2017

43.6K

Related Experiment Videos

Last Updated: Jan 26, 2026

Production of Nurr-1 Specific Polyclonal Antibodies Free of Cross-reactivity Against Its Close Homologs, Nor1 and Nur77
12:30

Production of Nurr-1 Specific Polyclonal Antibodies Free of Cross-reactivity Against Its Close Homologs, Nor1 and Nur77

Published on: August 17, 2015

7.9K
Kinematics and Ground Reaction Force Determination: A Demonstration Quantifying Locomotor Abilities of Young Adult, Middle-aged, and Geriatric Rats
10:28

Kinematics and Ground Reaction Force Determination: A Demonstration Quantifying Locomotor Abilities of Young Adult, Middle-aged, and Geriatric Rats

Published on: February 22, 2011

20.1K
Generation of Murine Monoclonal Antibodies by Hybridoma Technology
09:42

Generation of Murine Monoclonal Antibodies by Hybridoma Technology

Published on: January 2, 2017

43.6K

Area of Science:

  • Endocrinology
  • Immunology
  • Biochemistry

Background:

  • Gastrin is a key hormone regulating gastric acid secretion.
  • Accurate measurement of gastrin is crucial for diagnosing gastrointestinal disorders.
  • A well-characterized antibody is essential for reliable gastrin immunoassays.

Purpose of the Study:

  • To recharacterize a historically significant gastrin polyclonal antibody.
  • To assess the antibody's performance characteristics, including specificity and matrix effects.
  • To establish a reference range for fasting gastrin concentrations in a normal population.

Main Methods:

  • Radioimmunoassay (RIA) techniques were employed.
  • Specificity of the polyclonal antibody was evaluated.
  • The influence of different biological matrices on assay performance was investigated.
  • Fasting gastrin levels were measured in a cohort of normal subjects.

Main Results:

  • The recharacterization provides updated data on the gastrin polyclonal antibody's performance.
  • Specificity and matrix effects were quantified, informing assay optimization.
  • A reference range for circulating fasting gastrin was established for normal individuals.

Conclusions:

  • The study provides essential data for the continued use and interpretation of assays employing this gastrin antibody.
  • Updated characterization ensures the reliability of gastrin measurements.
  • Established reference ranges aid in the clinical assessment of gastrin-related conditions.